Mironid
Mironid develops small-molecule medicines for inherited kidney disease, with a lead programme targeting autosomal dominant polycystic kidney disease.
$46MSeries B
ParticipantSP
Sofinnova Partners
Activity from announced rounds
Activity in this selectionUnited Kingdom · Oct 12, 2026 · Jul 15, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $46M 1 disclosed · full round size, not this investor’s share